Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Conditions:   Relapsed/Refractory Rhabdomyosarcoma;   Non-rhabdomyosarcoma Soft Tissue Sarcoma;   Ewing Sarcoma Intervention:   Drug: Eribulin mesylate Sponsor:   Eisai Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials